deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00118274

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma

Sponsor: Craig L Slingluff, Jr

Conditions Melanoma (Skin)
Interventions cyclophosphamide incomplete Freund's adjuvant melanoma helper peptide vaccine multi-epitope melanoma peptide vaccine tetanus toxoid helper peptide
Updated 10 times since 2017 Last updated: Mar 25, 2021 Started: Mar 31, 2005 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00118274, this PHASE1/PHASE2 trial focuses on Melanoma (Skin) and remains completed. Sponsored by Craig L Slingluff, Jr, it has been updated 10 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotUnknown Status~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~May 2021 · 4 months · monthly snapshotCompleted~May 2021 – ~Dec 2022 · 19 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. May 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

  4. Feb 2017 — Sep 2017 [monthly]

    Unknown Status PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE1_PHASE2

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Craig L Slingluff, Jr
  • National Cancer Institute (NCI)
Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations